IQVIA Holdings (LTS:0JDM) FCF Margin % : 14.66% (As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is IQVIA Holdings FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. IQVIA Holdings's Free Cash Flow for the three months ended in Sep. 2024 was $571 Mil. IQVIA Holdings's Revenue for the three months ended in Sep. 2024 was $3,896 Mil. Therefore, IQVIA Holdings's FCF Margin % for the quarter that ended in Sep. 2024 was 14.66%.

As of today, IQVIA Holdings's current FCF Yield % is 5.38%.

The historical rank and industry rank for IQVIA Holdings's FCF Margin % or its related term are showing as below:

LTS:0JDM' s FCF Margin % Range Over the Past 10 Years
Min: 6.19 Med: 8.83 Max: 16.59
Current: 12.8

During the past 13 years, the highest FCF Margin % of IQVIA Holdings was 16.59%. The lowest was 6.19%. And the median was 8.83%.

LTS:0JDM's FCF Margin % is ranked better than
81.94% of 216 companies
in the Medical Diagnostics & Research industry
Industry Median: -5.655 vs LTS:0JDM: 12.80

IQVIA Holdings FCF Margin % Historical Data

The historical data trend for IQVIA Holdings's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IQVIA Holdings FCF Margin % Chart

IQVIA Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

7.53

11.82

16.59

11.01

10.01

IQVIA Holdings Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
FCF Margin %	Get a 7-Day Free Trial															11.70	14.68	10.09	11.67	14.66

Competitive Comparison of IQVIA Holdings's FCF Margin %

For the Diagnostics & Research subindustry, IQVIA Holdings's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IQVIA Holdings's FCF Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, IQVIA Holdings's FCF Margin % distribution charts can be found below:

* The bar in red indicates where IQVIA Holdings's FCF Margin % falls into.

IQVIA Holdings FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

IQVIA Holdings's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	1500	/	14984
	=	10.01 %

IQVIA Holdings's FCF Margin for the quarter that ended in Sep. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Sep. 2024 )	/	Revenue (Q: Sep. 2024 )
	=	571	/	3896
	=	14.66 %

IQVIA Holdings FCF Margin % Related Terms

Thank you for viewing the detailed overview of IQVIA Holdings's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

IQVIA Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » IQVIA Holdings Inc (LTS:0JDM) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

IQV:USA IQV:Mexico QTS:Germany I1QV34:Brazil IQVH:Austria

Address

2400 Ellis Road, Durham, NC, USA, 27703

Website

https://www.iqvia.com

IQVIA is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.

IQVIA Holdings Headlines

No Headlines